Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-30
2010-06-01
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S126000
Reexamination Certificate
active
07728017
ABSTRACT:
The present invention provides compounds useful as inhibitors of c-Met tyrosine kinase. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various proliferative disorders.
REFERENCES:
patent: 02/12236 (2002-02-01), None
patent: 2005/010005 (2005-02-01), None
patent: 2007/075567 (2007-07-01), None
Deshmukh et al. Indian Journal of Chemistry (1984), 23B (8), 793-5.
Kelarev, V. I. et al., Synthesis of 1,2,4,-triazolo [3,4-B]-1,3,4-thiadiazole derivatives with the fragments of sterically-hindered phenol lzvestiya Vysshikh Uchebnykh Zavedenii, Khimiya i Khimicheskaya Teckhnologiya, 2003, vol. 46(7), Abstract & Compound CAS Nos. 773072-92-7, 773072-93-8, 773072-94-9, 773072-98-3, 773073-06-6, 773073-07-7; Database CA Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN Database accession No. 2004:400043; CODEN: IVUKAR; ISSN: 0579-2991; XP002434078.
Wermuth C G: “Molecular Variations Based on Isosteric Replacements” Practice of Medicinal Chemistry, 1996, pp. 203-237, Academic Press, USA; XP002190259.
Udupi, R. H. et al., “Synthesis and Biological evaluation of 3-substituted-4-[6′-methoxynapth-2′ -yl] propionamido-5-mercapto-1,2,4-triazoles” Indian Journal of Heterocyclic Chemistry, 2002, vol. 12(1), Abstract & Compound CAS No. 497085-79-7P; Database CA Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN Database accession No. 2002:775245; CODEN: IJCHEI; ISSN: 0971-1627; XP002434079.
Liu, Su-Yan et al., “Synthesis of 6-nitrobenzimidazole derivatives” Gaodeng Xuexiao huaxue xuebao, 2000, vol. 21 (9) Abstract & Compound CAS Nos. 326587-38-6, 326587-39-7, 326587-40-0, 326587-41-1, 326587-42-2, 326587-43-3, 326587-44-4, 326587-45-5, Database CA Chemical Abstract Service, Columbus, Ohio, US, retrieved from STN Database accession No. 2000:830662 CODEN: Kthpdm; ISSN: 0251-0790; XP00243080.
Udupi, R. H. et al., “Synthesis and biological evaluation of 3-substituted 4-[2′-(4″-isobutylphenyl) propionamido]-5-mercapto-1,2,4-triazoles and their derivatives” Journal of the Indian Chemical Society, 2000, vol. 77(6), Abstract & Compound CAS No. 297179-65-8; Database CA Chemical Abstract Service, Columbus, Ohio, US, retrieved from STN Database accession No. 2000:494154; CODEN: JICSAH; ISSN: 0019-4522; XP002434081.
Christensen J G et al., “c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention” Cancer Letters, 2005, vol. 225, pp. 1-26; New York, NY, US; ISSN: 0304-3835; XP004939070.
Basu N. K. et al., “s-Triazolopyridazines: synthesis as potential therapeutic agents” Journal Chemical Society, 1963, pp. 5660-5664; XP009088851.
Aronov Alexander
Come Jon H.
Deininger David D.
Lauffer David J.
Li Pan
Habte Kahsay T
Pearson Daniel A.
Vertex Pharmaceuticals Incorporated
LandOfFree
Inhibitors of c-Met and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of c-Met and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of c-Met and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244926